Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy.

ABSTRACT:

Background

Most patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) are diagnosed noninvasively, using nuclear imaging and monoclonal protein testing. However, concerns have been raised that some may receive an ATTRwt-CM diagnosis based on incomplete evaluations (not based on current consensus recommendations). Using a cohort of US Medicare Fee-for-Service patients, we aimed to examine the frequency and cadence of diagnostic testing for ATTRwt-CM.

Methods

In this retrospective observational cross-sectional study, administrative de-identified claims data from 2018 to 2022 were derived from patients aged ≥65 years who had at least one claim for ATTRwt-CM and heart failure or cardiomyopathy, and ≥2 years of continuous Medicare enrollment before the first AT

SUBMITTER: Witteles RM 

PROVIDER: S-EPMC12606490 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature